SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Creech Todd A

(Last)

(First)

(Middle)

C/O ZS PHARMA, INC.

1100 PARK PLACE, SUITE 300

(Street)

SAN MATEO

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ZS Pharma, Inc. [ ZSPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Former Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2015

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2015		M		20,000	A	$2.13	20,000	D
Common Stock	08/20/2015		S		20,000	D	$50.03	0	D
Common Stock	08/21/2015		M		50,000	A	$2.13	50,000	D
Common Stock	08/21/2015		S		50,000	D	$49.76⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Options	$2.13	08/20/2015		M			20,000	⁽²⁾	⁽²⁾	Common Stock	20,000	$2.13	260,771	D
Employee Stock Options	$2.13	08/21/2015		M			50,000	⁽²⁾	⁽²⁾	Common Stock	50,000	$2.13	210,771	D

Explanation of Responses:

1. Mr. Creech sold 50,000 shares of common stock at prices ranging from $49.50 per share to $50.01 per share.

2. Mr. Creech was granted options to purchase 280,771 shares of common stock at an exercise price of $2.13 per share on August 16, 2013, of which 25% of the shares subject to such option vested on August 12, 2014, the first anniversary of the vesting commencement date, with the remaining 75% of the options vesting monthly in substantially equal installments over the following 36 months, subject to Mr. Creech's continuing to provide services to the company through each vesting date. Mr. Creech exercised 20,000 of such options on August 20, 2015 and 50,000 of such options on August 21, 2015, all at the exercise price of $2.13 per share.

Remarks:

Mr. Creech no longer serves as the Chief Financial Officer of ZS Pharma, Inc., effective as of June 15, 2015.

	/s/Todd A. Creech	08/24/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.